Noteworthy News Articles on Mental Health Topics, August 28-31, 2007

Not a Game: Simulation to Lessen War Trauma
Amanda Schaffer, New York Times- 8/28/2007

The sun shines on an empty Iraqi street. A Blackhawk helicopter circles overhead. The aromas of spices from a market fill the air. Suddenly, insurgents hiding on a roof launch a rocket-propelled grenade. The ground shakes violently and plumes of black smoke cloud your vision. Those images, produced when a person puts on a headset, are at the heart of Virtual Iraq, a simulation created to treat Iraq war veterans suffering from post-traumatic stress disorder.
      By repeatedly encountering sights, sounds, smells and rumblings that evoke painful memories, experts say, veterans with the disorder can begin to reprocess traumatic events and become desensitized to them, perhaps suffering fewer side effects like insomnia, nightmares and flashbacks. The simulation is available to a small number of patients at sites including the Veterans Administration Medical Center in Manhattan, the Naval Medical Center in San Diego, the Emory University School of Medicine in Atlanta and Walter Reed Army Medical Center in Washington.
     So-called exposure therapy, in which patients are asked to confront memories of a trauma by imagining and recounting it in painstaking detail, has long been a first-line psychological treatment for post-traumatic stress disorder. But the bells and whistles of virtual reality may make exposure therapy more effective, said Michael Kramer, a clinical psychologist at the Veterans Administration hospital in Manhattan who is overseeing the introduction of Virtual Iraq there. “One of the hallmarks of P.T.S.D. is avoidance,” Dr. Kramer said. “Patients spend an awful lot of time and energy trying not to think about it or talk about it. But behaviorally, avoidance is what keeps the trauma alive. “With virtual reality, we can put them back in the moment. And we can do it in a gradual, controlled way.”
     Virtual Iraq features two scenarios. In one, patients navigate the streets of a generic Iraqi city, walking past buildings, cars, civilians and markets. With the touch of a therapist’s keypad, a little boy might appear on a street corner and wave, apparently in friendship, or a man might stumble down the middle of the street calling for help, a sight that provokes anxiety in some veterans who have come to fear ruses. In the other scene, veterans ride in a Humvee. Other vehicles might slow down in front of them, and strangers might open fire. Enemy combatants might appear under bridges. Objects dotting the roadside might explode as the Humvee passes. The patient cannot shoot back at the insurgents and also cannot die or be wounded in the simulation.
     In choosing which stimuli to introduce, the therapist’s goal is to evoke the conditions present when specific traumatic events occurred, as accurately as the simulation will allow. Smells like spices, burning garbage or body odor can be emitted in four-second puffs. And the scene can be set to day or night, sun or fog or even a sandstorm.
     Given the power of traumatic memories, Dr. Kramer said, it is important “to go at a pace that the veteran can tolerate, so that he isn’t overwhelmed,” and he starts to realize that the memories cannot harm him. One risk of introducing potent material too fast is that a veteran could become retraumatized and perhaps unwilling to continue other kinds of therapy, as well.
     Not all patients with the stress disorder are likely to benefit from this therapy. Veterans who lack basic coping mechanisms, are actively having flashbacks or who have unaddressed problems with substance abuse should probably not enter the simulator, Dr. Kramer said.
     Dr. Albert Rizzo, the director of the Virtual Environments Lab at the University of Southern California who helped develop the simulator, said, “It’s a hard treatment for a very hard problem.” Dr. Rizzo first created a simulation for Iraq veterans with the disorder in 2003, by modifying the Xbox game Full Spectrum Warrior. In 2004, he and Ken Graap, president and chief executive of Virtually Better in Decatur, Ga., received financing from the Office of Naval Research to develop the current simulation, with extensive feedback from veterans and active-duty members of the military. Virtually Better also offers a Virtual Vietnam, as well as programs to address fear of heights and flying, social phobias and addictive behaviors.
     Exposure therapy may not be enough for veterans with complicated symptoms resulting from chronic stress and multiple traumatic episodes, said Dr. Rachel Yehuda, director of the post-traumatic stress disorder program at the James J. Peters Department of Veterans Affairs Medical Center in the Bronx. “I don’t believe,” she said, “that any study of exposure therapy for combat-related P.T.S.D. has shown a clinically significant improvement” in more than half the patients. “While I would offer it to a veteran in a heartbeat, I would be prepared for the fact that it might have to be supplemented with other forms of assistance” like medication and social services, she said. “If we’re too enthusiastic,” Dr. Yehuda added, “then people may expect veterans to be cured after 12 weeks, and it just doesn’t work that way.”
     Hunter Hoffman, a cognitive psychologist at the University of Washington in Seattle, said: “With the growing ranks of Iraq war veterans who have developed P.T.S.D., now is the time for them to receive effective treatment, not 20 years from now. “We know from Vietnam that for most patients diagnosed with P.T.S.D., these problems don’t just go away over time.”



So, What Made Me an Addict?

Maia Szalavitz, Washington Post- 8/28/2007

Many people think they know what addiction is, but despite non-experts' willingness to opine on its treatment and whether Britney or Lindsay's rehab was tough enough, the term is still a battleground. Is addiction a disease? A moral weakness? A disorder caused by drug or alcohol use, or a compulsive behavior that can also occur in relation to sex, food and maybe even video games?

As a former cocaine and heroin addict, these questions have long fascinated me. I want to know why, in three years, I went from being an Ivy League student to a daily IV drug user who weighed 80 pounds. I want to know why I got hooked, when many of my fellow drug users did not.

A bill was introduced in Congress this spring to change the name of the National Institute on Drug Abuse (NIDA) to the National Institute on Diseases of Addiction, and the National Institute on Alcoholism and Alcohol Abuse (NIAAA) to the National Institute on Alcohol Disorders and Health. In a press release introducing the legislation, Sen. Joseph R. Biden Jr. (D-Del.) said, "By changing the way we talk about addiction, we change the way people think about addiction, both of which are critical steps in getting past the social stigma too often associated with the disease."

But opinion polls find weak support for the concept of addiction as a disease, despite years of advocacy by such agencies as NIDA and NIAAA and by recovery groups. A 2002 Hart poll found that most people thought alcoholism was about half disease, half weakness; just 9 percent viewed it wholly as a disease.

So what does science have to say? Addiction research has advanced dramatically since my high school years in the early 1980s, when I began using marijuana and psychedelics, then cocaine, in the hope they would relieve my social isolation. My progression from psychedelics to coke was fed by a definition of addiction that still causes widespread misunderstanding. In 1982 -- around when I first tried cocaine -- Scientific American published an article claiming it was no more addictive than potato chips. This was based on the fact that cocaine users, unlike heroin users, do not become physically sick when they try to stop taking their drug.

Addiction, by this reasoning, is a purely physiological process, one that results from drug-induced chemical changes in the brain and body. Over time, with heroin and similar drugs, the article explained, the user develops tolerance (needs more of the drug to experience the same effect) and eventually becomes physically ill if he doesn't have access to an adequate dose. Addiction, by this theory, is primarily an attempt to avoid physical withdrawal.

I bought into this idea because it was confirmed by my experience: I never had a problem stopping marijuana, LSD or mushrooms, none of which cause significant physical dependence. I expected cocaine to be similar and, therefore, safer than heroin. With no physical withdrawal to avoid, stopping should be a snap. Or so I thought.

By the time I got suspended from college for my involvement with cocaine, I was smoking it, often daily. And because I believed that my suspension meant I'd already ruined my life, I felt I had no reason not to try heroin. I just didn't care.

Heroin became my drug of choice. It calmed me, gave me distance from my obsessions and anxieties. Over time, cocaine made me feel anxious, but heroin always soothed and smoothed. I continued taking both, injecting higher and higher doses.

Today's most widely accepted definition of addiction -- used in psychiatry's latest edition of its diagnostic manual, the DSM-IV-TR -- recognizes that compulsive use of a substance despite negative consequences is key. And that's exactly what I experienced: At least six times, I made it through the physical sickness of heroin withdrawal -- the shaking, diarrhea and vomiting -- only to use again because I wanted the drug. This compulsive aspect helps explain why we can now consider video games and, yes, even potato chips more addictive than we did in the past.

But the DSM retains a focus on physical aspects of addiction: It calls addiction "substance dependence," suggesting that physical need is critical. Tolerance and withdrawal are part of the criteria used to diagnose the condition, even though pain patients taking opioids as directed may experience both and not actually be addicted. Studies find that less than 1 percent of people who take pain medications and don't have a past history of drug problems become addicted. Many pain patients who stop opioids after the source of their pain has been removed even undergo withdrawal without realizing it: It's called "hospital flu." But the vast majority have no difficulty refusing further medication.

As a result, experts -- including NIDA director Nora Volkow -- have called for the official name of the disorder to be changed from "substance dependence" to "addiction" in the next edition of the DSM. They say the confusion between physical dependence and addiction leads to under-treatment of pain: Surveys find many patients, even those who are dying, don't receive enough medication for effective relief. Physicians are even criminally prosecuted for "over-prescribing" when patients with painful conditions become physically dependent on opioid drugs.

But if physical symptoms don't define addiction, does it follow that addiction is a brain disorder? Matters are murky here as well.

While researchers have argued that addiction is a disease because drugs change the brain, the fact is, most users -- even of drugs such as heroin -- do not become addicted. While 50 percent of American soldiers in Vietnam tried heroin or opium, only 10 percent continued to use such drugs after returning home, and just 1 percent became long-term opioid addicts, according to a federally funded study by University of Washington sociologist Lee Robins.

Further, all brain changes are not indicative of disease. Learning itself changes the brain. FMRI brain scans of London taxi drivers and virtuoso violinists show changes that embody the effects of years of practice in relevant brain regions -- however, no one argues that this means they are ill.

As a result, scans alone cannot prove that addiction is a disease. "The idea that fMRIs can explain addiction is based on the same unscientific grounds as phrenology," says psychologist Stanton Peele, a longtime opponent of seeing addiction as a disease and author of the new book "Addiction-Proof Your Child."

In my own experience, I stopped using when addiction threatened my core values. On my last day taking heroin, I found myself considering seducing a man to get drugs. Because I despised this guy and had a serious boyfriend, I was shocked that I would consider it: I knew that that was addictive behavior. At that point, my personal definition of an addict was someone who violates her own principles to get drugs. I sought treatment the next day and never used cocaine or heroin again.

In Peele's view, addiction is a bad habit, a learned behavior that gets out of hand, an exaggeration of the human tendency to put off pain in favor of immediate pleasure. Even, in some instances, a rational choice when life presents little opportunity for connection, purpose or joy.

Volkow disagrees. She has pioneered brain-imaging research on addictions, looking for ways in which they differ from ordinary learning. "Drugs of abuse affect multiple systems, not just those involved with learning and memory," she says, adding that they interfere with regions that put the brakes on unwanted behavior.

"What happens in the brain of the addicted person is equivalent to a state of deprivation. It changes the brain from operating in a situation where someone has a choice and does something because he wants to do it to a situation where it feels like need," she says.

That, too, comports with my experience: Cocaine seemed to affect my motivation, leading me to take more even when I knew it would fuel a burst of paranoia, not euphoria. While at first it brightened and enhanced other joys, over time it sucked the pleasure and color out of my life. But although I could consciously see this, I felt I couldn't stop.

Another relevant factor seems to have been my youth: We now know that the frontal cortex, the seat of judgment, the region that should apply the brakes, is not fully developed until the early to mid-20s. I quit at 23; when I look back on my behavior now, the sheer stupidity of some of the risks I took shocks me. Genetic research also suggests that certain people are more prone to addiction, particularly those with other mental illnesses such as depression, a condition I also have.

So does that make it a disease? Some would argue that my response to treatment proves it. I underwent seven days of detox, 30 days of rehab, then three months in a halfway house and ongoing self-help support. Later, antidepressant medication helped reduce the distress that I'd previously self-medicated with heroin.

As Thomas McLellan, chief executive of the Treatment Research Institute in Philadelphia and professor of psychiatry at the University of Pennsylvania, notes, treatment for addiction is as effective as treatment for other chronic diseases that involve lifestyle change, such as diabetes and asthma.

Just calling it a disease, however, may not reduce the moral stigma tied to addiction -- as some hope. University of Nevada psychologist Steven Hayes is studying people's unconscious responses to words. "Disease" was as stigmatizing overall as clearly pejorative terms such as "drunk," and was more stigmatizing overall than such terms as "addict" and "intoxicated," he says.

Consider the historical treatment of people with epilepsy or "madness." Or the fact that we think "tough" rehabs are good, despite evidence suggesting otherwise -- though we wouldn't even contemplate "getting tough" with diabetics. Says McLellan: "Yes, people with epilepsy were sent to priests and shamans, too -- but that was the 18th century. Addicted people are still told to get religion."

The program I attended, for example, told me that I would not recover if I didn't surrender to a higher power, make amends and pray. This is not how most diseases are treated.

Further, labeling people with a brain disease characterized by lack of self-control can have negative consequences, particularly for adolescent users, most of whom are not addicts, suggest NIDA surveys and other research. In many teen rehabs, youths are told that they have "chronic, progressive" illness with a 90 percent chance of relapse. Forcing teens, whose identity is not fully formed, to accept an "addict" identity can be a self-fulfilling prophecy.

As Peele points out, "Self-efficacy and the image of the ability to control oneself are critical to recovery" -- as they are to maturation. For the same reason, it's a bad idea to tell people that without treatment, recovery is impossible. In fact, most addicts who recover do so without treatment. Among those who relapse, belief in the disease model is predictive of greater severity, research shows.

So is addiction disease or learned behavior? Given its complexity, some experts say, what probably matters most is which view best yields compassionate and effective treatment.

Maia Szalavitz is a senior fellow at Stats.org and the author, with Bruce D. Perry, of "The Boy Who Was Raised as a Dog and Other Stories From a Child Psychiatrist's Notebook" (Basic Books) and the author of "Help at Any Cost: How the Troubled Teen Industry Cons Parents and Hurts Kids" (Riverhead).



Headway in Developing a Faster-Acting Antidepressant
Denise Gellene, Los Angeles Times- 8/29/2007

After years of little progress, scientists are making headway in the search for a better, faster-acting antidepressant. Experiments with an anesthetic called ketamine have yielded important clues about the biology of depression, leading scientists to attack the mood disorder in new ways.
      Improved treatments are sorely needed. Depression affects about one in 10 adult Americans each year, while current drugs work in only 50% to 60% of patients, can cause sexual problems and take weeks to work. They also carry a small risk of suicidal thoughts and behaviors in adolescents and young adults. All existing antidepressant drugs work in much the same manner. They act on a handful of neurotransmitters -- brain chemicals that pass messages along defined pathways -- that belong to a family called monoamines and circulate in a relatively small portion of the brain.
     The most recognized of these neurotransmitters is serotonin, low levels of which have been linked to depression. Drugs such as Prozac and Celexa are aimed at raising serotonin levels available to the brain. The other transmitters targeted by antidepressants are dopamine and norepinephrine. Wellbutrin is an example of an antidepressant that boosts levels of these neurotransmitters but not serotonin.
     Scientists first discovered these neurotransmitters affect depression in the 1950s when they found that the tuberculosis drug iproniazid also lifted patients' moods. The drug blocks an enzyme that converted serotonin, dopamine and norepinephrine into inactive forms, and after some study the drug was marketed for depression. Pharmaceutical companies have developed drugs targeting the trio of neurotransmitters ever since.
     Because it is expensive to discover and develop new drugs, it is safer for pharmaceutical companies to stick with known biological targets than to head in risky new directions, said Dr. Carlos Zarate Jr., a researcher at the National Institute of Mental Health. As a result, "we have not made substantial gains in terms of antidepressants," Zarate said. But recent studies on ketamine have pushed researchers to change how they think about depression. The anesthetic acts on glutamate, the brain's most plentiful neurotransmitter, which circulates widely in the brain and hasn't been linked to depression in the past.
     In a small experiment led by Zarate last year, five of 18 people who received a single intravenous dose of ketamine experienced a dramatic lifting of their depression the first day and were still much better a week later. All patients in the experiment had first tried regular antidepressants but did not improve on them, according to the study published last August in the Archives of General Psychiatry. Similar fast improvements were found in a study of eight patients conducted at Yale Medical School and published in Biological Psychiatry in 2000. The rapid response was encouraging, Zarate said, suggesting that a faster-acting antidepressant may be possible. Current antidepressants take two to three weeks to begin working, and until recently, "it was just accepted as fact we couldn't do any better," he said.
     Dr. Gerard Sanacora, director of the depression research program at Yale Medical School, said the results also mean that glutamate may have a more direct role in depression than serotonin and other brain chemicals targeted by current antidepressants. "The fact that it acts so rapidly means that it is getting closer to the core of depression," Sanacora said.
     In some ways, it's surprising that researchers studying depression didn't suspect the role of glutamate, which is an amino acid, in the disorder sooner. Malfunctions in the glutamate system have long been linked to other psychological and neurological disorders, including schizophrenia and Alzheimer's disease. Glutamate has long been associated with learning and memory. "It is hard to image anything glutamate is not involved in," said Sanacora. "It is really what makes the brain run."
     Still, scientists haven't yet figured out how the glutamate system goes awry in depression. One theory is that glutamate leaks from brain cells, perhaps in response to chronic emotional stress, and causes changes in key brain structures.
     The hippocampus, which processes memory, and the parts of the cortex, where decisions are made, are known to be smaller in depressed people. Perhaps, Zarate said, excess glutamate caused cells in these brain structures to shrivel. High amounts of glutamate are toxic to brain cells and cause the death of some neurons in stroke patients, he noted.
     Ketamine is not approved for treating depression and Zarate said it was too soon to give it to patients outside the confines of a clinical trial. Ketamine can cause hallucinations and confusion and is sometimes abused as a club drug. In fact, he said, all patients who received the drug in his study reported out-of-body hallucinations. But studying the workings of ketamine in the brain may provide researchers with information that could lead to a new class of fast-acting antidepressants.
      Zarate and colleagues reported last month that ketamine blocks a glutamate receptor, called NMDA, on the surface of nerve cells. As a result, glutamate can't bind to it anymore and instead binds and activates another receptor, called AMPA. The increased activity of AMPA is what produces ketamine's mood-elevating effects, Zarate concluded. Drawing an analogy, he explained: "If you imagine a bifurcated garden hose and you block the left nozzle, you will get a massive amount of water through the right."
     A number of drugs that work on glutamate have been approved as treatments for neurological disorders and are now being tested against depression. Among them are Forest Laboratories' Namenda, which is approved to treat Alzheimer's disease symptoms, and Sanofi-Aventis' Rilutek, which is used to slow amyotrophic lateral sclerosis, or Lou Gehrig's disease. Neither is expected to be a big breakthrough. Namenda is not a powerful blocker of the NMDA receptor and Rilutek doesn't work very quickly. Zarate's group at the National Institute of Mental Health is planning a trial in which depressed patients will receive a dose of ketamine, followed by regular doses of Rilutek, which scientists hope will maintain patients' recovery.
     Other drugs targeting glutamate are on the way, although it could be many years before they reach patients. For example, an experimental Merck & Co. drug that blocks a sub-unit of the NMDA receptor is now in clinical trials. In May, Pfizer Inc. reported on a study of 30 depressed patients who received an experimental intravenous drug that also blocks that same sub-unit of the NMDA receptor. The antidepressive effect of the drug, CP-101,606, was similar to that of ketamine, said Dr. Sheldon H. Preskorn, chairman of the department of psychology and behavioral sciences at the University of Kansas School of Medicine-Wichita, who led the study. Within 24 hours, more than half of the patients in the study had a "bright affect," were smiling spontaneously and talked more rapidly, Preskorn said. Their about-face was so remarkable "that had I not seen it myself, I would not have believed it," Preskorn said.
     Many questions remain. No one knows whether depressed patients will tolerate or respond to a second dose of a ketamine-like drug. Patients in trials so far have received only one dose. In addition, the rapid personality overhauls induced by the drugs have implications for family and social relationships that will need to be addressed, probably through counseling or therapy, Preskorn said. "The drugs deal with the hardware problem," he said. "Once that's done, we still have to deal with the software issue."
     Here are some other drugs under study as possible antidepressants.
* Agomelatine, yohimbine: Works on the sleep-wake cycle.
* Scopolamine: Targets the brain's cholinergic system.
* Mifepristone, CRF1 antagonists: Lowers levels of the stress hormone cortisol.
* Remicade: Reduces inflammation.



Mental Health Teams Give Pediatricians a 2d Opinion
Carey Goldberg, Boston Globe- 8/30/2007

SPRINGFIELD -- The voicemail delivered an SOS from an anxious pediatrician: "This kid is really out of control. He's basically destroying his family. Can someone please call me?" Dr. Barry Sarvet, a Yale-trained child psychiatrist, returned the call within minutes, to offer guidance. He has been taking such calls for three years, as part of the Massachusetts Child Psychiatry Access Project, a program that allows virtually any Massachusetts doctor who treats children to call for an immediate consultation about any patient's mental health -- for free.
      The first of its kind in the nation, the program has been ramping up since 2004 and now covers virtually the entire state. Psychiatric specialists in six regional teams offer phone advice within half an hour, face-to-face evaluations within days, and help obtaining mental health services for children and teens. The project, funded by the state Department of Mental Health, provides support at a time when pediatricians are likelier than ever to be asked to prescribe Ritalin, diagnose depression, and screen for emotional distress -- work that many were not trained to do. It also conserves a scarce resource: child psychiatrists. They are in short supply around the country, and waits for appointments can stretch to months. The new project helps primary care physicians handle relatively simple mental health issues, such as moderate depression or anxiety, freeing up the psychiatrists' time for more complex and severe cases. "In their heart of hearts, some pediatricians would like to be able to refer a child to a psychiatrist as if they were referring to a cardiologist" -- simply handing the patient over to a specialist, said Dr. Joseph Gold, chief medical officer of McLean Hospital. "But given the shortage of child psychiatrists, the pediatricians recognize that in some cases, it's enough if they can just get an opinion."
     Massachusetts has the highest per-capita number of child psychiatrists in the nation, said Dr. John Straus, vice president for medical affairs of the Massachusetts Behavioral Health Partnership, which contracts with the state to run the project, among other services and programs. But they are still in short supply here, perhaps because many occupy academic or administrative positions and do not practice, Straus said. Washington state is about to launch a program modeled on Massachusetts', Straus said, and other states have expressed interest as well.
     Handing out psychiatric opinions over the phone may sound like a recipe for a lawsuit. But Sarvet said that the project's consultants emphasize that their function is essentially educational, sharing information about state-of-the-art psychiatric practices and standards, and recommended drug dosages. Also, he said, its specialists tend toward highly conservative and circumspect opinions. If they are at all unsure, they ask that the child come in for a face-to-face evaluation. And they do not write prescriptions themselves. A typical opinion, he said, might sound like this: "You describe a history consistent with a diagnosis of depression, and best practice is to refer the patient to a therapist and offer the option of starting medication." The project essentially provides a systematic version of an age-old practice in medicine, the "curbside" or "hallway" consult, in which a doctor stops a colleague with more expertise and says, "I have a case like this, what would you do?" Straus said.
     At Redwood Pediatric and Adolescent Medicine in East Longmeadow, the team's nurse-practitioner and three pediatricians call the project's Springfield office about once a week, said Dr. John Kelley, one of its physicians. "There's a big problem with access to mental health care for kids," he said. "It's a huge issue for us, because primary care doctors are being asked to take on more and more of a role in something we're absolutely not trained in. This program has been just wonderful because what it gives us is someone I can call."
     Kelley said he appreciates the "care coordination" aspect: Each team has a staffer whose job is to find the mental health services a family needs for their child, and that accepts their insurance. The staffer serves as a guide through the confusing world of "family stabilization," "partial hospitalization," and "crisis intervention." "Before," Kelley said, "we had to beg and grovel to get a kid into mental health services with psychiatric involvement."
     In an ideal world, Kelley said, he would be able to simply refer patients to pediatric psychiatrists whenever needed, and they would take over. But "this is a kind of an in-between," he said. "It's a whole heck of a lot better than it was before the program started." Other pediatricians seem to agree with him; the project has polled them, and found that the great majority think access to child psychiatrists has improved since it began, even though the number of psychiatrists statewide -- about 280 who see patients -- has not increased. The project does not accept calls from families, therapists, or social workers.
      Parents of mentally ill children say that waits for psychiatric help are still too long. But, said Lisa Lambert, director of the Parent/Professional Advocacy League, "we're hearing fewer stories about pediatricians who are uncomfortable or reluctant to deal with mental health needs." The project's most obvious effect, she said, "is that families just aren't telling us as much about how they're sort of hitting a blank wall in pediatricians' offices."
     On Tuesday morning, Sarvet exchanged a brief, efficient phone call with a pediatrician concerned about a teenaged boy whose anxiety had become so overwhelming that he was refusing to leave the house. He had missed the first day of school, and seemed to be headed for crisis. Sarvet told the pediatrician that he had discussed the case with the team's therapist, Jodi Devine, a licensed social worker, and they wanted the boy to come in right away for a "level of care" evaluation, because he might need to be in a partial hospitalization program, and they thought they could find him a spot in one. The pediatrician had prescribed the antidepressant Zoloft and a tranquilizer, and Sarvet recommended keeping those medications for now. If not for the project, Sarvet said, the pediatrician would probably have felt compelled to tell the boy simply to go to the emergency room and wait for help.



Killer's Parents Describe Attempts to Help Isolated Son
Bridgid Schulte, Washington Post- 8/31/2007

Sometimes, Hyang Im Cho would become so frustrated with her son, Seung Hui Cho, that she would shake him. He rarely spoke. And when he did, it was just a few words, barely above a whisper. He never looked anyone in the eye. It was as if he lived walled off in a world of his own. Try as she might -- with countless visits to counselors and psychologists, treatment with antidepressants or art therapy, and attempts to find him friends at basketball camp or taekwondo or church -- no one could break through. Like any mother, she wanted her son to fit in. Like any immigrant, she felt that no sacrifice was too great to make sure he found a place for himself in this new country, even if it meant overcoming the deeply ingrained stigma in Korean culture of admitting mental illness. She knew he was troubled and isolated. But it wasn't until her son killed 32 students and teachers at Virginia Tech on April 16 that she knew just how twisted his private world had become. And how little she knew him.
      Hyang Im Cho, along with her husband, Sung Tae Cho, and daughter, Sun Kyung, spoke about Seung Hui Cho to the panel appointed by Gov. Timothy M. Kaine to investigate the Virginia Tech shootings. The panel's report, formally released yesterday, paints the most complete portrait to date of Cho's frail and sickly childhood; his hopeful middle and high school years bolstered by intensive psychological therapy, medication and a supportive school environment; his misplaced aspirations to become a famous writer; and, as that dream slipped away, his descent into madness.
     The report also provides for the first time some perspective from Cho's family. They were shocked when they learned of his violent writings. Cho had always been so secretive, typing away on his computer but refusing to share what he wrote. They had no idea that he had been briefly hospitalized at a psychiatric institution during his junior year at Virginia Tech and had been declared mentally ill. The son, the hospital and the court never told them. "We would have taken him home and made him miss a semester to get this looked at," the Chos told the panel. "But we just did not know . . . about anything being wrong."
     Until now, the family's only public comment had been a statement of deep remorse in the days after the tragedy. "We never could have envisioned that he was capable of so much violence," they wrote at the time. The Chos, who own a townhouse in Centreville, have been in seclusion since April. Cho's sister, a graduate of Princeton University, has been on leave from her job as a contractor with the State Department. Wade Smith, the Chos' attorney, who released the statement, did not return repeated phone calls yesterday. Smith arranged for the Chos to meet with the panel for a three-hour interview. Sun Kyung translated, as she had for many of her brother's conferences.
     Although the panel said neither it nor the police had uncovered a motive for Cho's rampage, his sister provided a key piece of the puzzle. Cho began his college career as a business information technology major but, by the time he was a sophomore, decided to switch to English, which was one of his weakest subjects. Nevertheless, he was convinced that he could be a great writer. He had written a novel, which he described to teachers as "sort of like Tom Sawyer except that it's really silly and pathetic," the report said. Later that year, after his sister found a rejection letter from a New York publishing house, she noticed that he became increasingly depressed and detached. His English grades ranged from B's to D's, and his rage grew as he felt no one understood him or his talent.
     Life had always been difficult for Cho. As an infant in South Korea, he developed whooping cough and was hospitalized with pneumonia. Doctors told the family that he had heart troubles and, when he was 3, they performed an invasive procedure to examine him. From then on, Cho did not like to be touched. In Korea, Cho had a few friends he played with. But once the family moved to the United States in 1992 to provide a better education for the children, Cho became more withdrawn. If he talked to anyone at all, it was to his sister. Even then, he would never tell her what he was thinking or feeling. She knew he was being taunted for his accent and inability to speak English, as was she. But whenever she'd ask him about it, he would always say he was "okay."
     Even that limited communication disappeared when a visitor came to the home. The family noticed that Cho's palms would become sweaty, he would freeze, would sometimes cry and was able only to nod yes or no. His parents, by then working six days a week at dry cleaners, pressured him to talk. His mother urged him to "have more courage," the report said. When Cho was still in elementary school, the family decided to "let him be the way he is," the report said.
     In 1997, the summer before he entered middle school and on the school's recommendation, the family took Cho to the Center for Multicultural Human Services, where he saw an art therapist and a psychiatrist who diagnosed a severe social anxiety disorder. "It was painful to see," one of the psychiatrists told the panel. The Chos took turns leaving work early to get their son to his sessions every week. In art therapy, Cho made houses out of clay that had no windows or doors. Sometimes, when the therapist explained that his artwork showed how inadequate he must feel, Cho's eyes would fill with tears.
     In 1999, during the spring of eighth grade, the clay houses morphed into disturbing caves and tunnels. Cho wrote in a school assignment about wanting to "repeat Columbine." A psychiatrist diagnosed selective mutism -- the inability to speak in certain circumstances because of profound social anxiety -- and prescribed paroxetine, an antidepressant. The drug treatment was discontinued after one year because Cho seemed much improved.
     When Cho was at Westfield High School in Chantilly, his inability to communicate and lack of social skills landed him in a special education program designed to help him succeed in school. He was excused from participating in class discussions and received language therapy once a week. The plan enabled him to graduate with a 3.52 grade-point average in a demanding honors program. As a junior, he resisted further therapy. "There is nothing wrong with me," he complained to his parents, according to the panel report. "Why do I have to go?"
     When Cho was a senior, his guidance counselor strongly encouraged him to attend a small college close to home. But Cho had his sights set on Virginia Tech, where he was accepted on the strength of his grades and SAT scores. When his school records were sent, as is common practice, there was no mention of the special education provisions or his condition. At Virginia Tech, he became increasingly isolated and behaved in a bizarre manner, stabbing a carpet with a knife at a party and yelling at a teacher who told him to drop a class. His writing likewise became increasingly violent. The night before their once-invisible son would become infamous for the worst mass shooting by a lone gunman in U.S. history, the Chos had their weekly Sunday evening phone call with him. It was typical. He was fine. No, he didn't need money. His parents ended with, "I love you." The report does not say whether Cho answered.